STARPHARMA HOLDINGS LIMITED — Director's Dealing 2021

Sep 30, 2021

Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Starpharma Holdings Limited
ABN	20 078 532 180

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jacinth K Fairley
Date of last notice	30 August 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.
Date of change	1 October2021
No. of securities held prior to change	1.3,252,386 OrdinaryShares (direct)
	2.668,048Ordinary Shares (indirect)Fairley Family Super Fund Pty Ltd
	3.55,000 Ordinary Shares (indirect) DrIan Fraser
	4.5,234,242Performance Rights(SPLAK)
Class	Performance Rights
Number acquired	Nil
Number disposed	224,712Performance Rights forfeited
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	Nil

+ See chapter 19 for defined terms.

No. of securities held after change	1.3,252,386 OrdinaryShares (direct)
	2.668,048Ordinary Shares (indirect)Fairley Family Super Fund Pty Ltd
	3.55,000 Ordinary Shares (indirect) DrIan Fraser
	4.5,009,530Performance Rights(SPLAK)
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back	Forfeiture of 189,668Performance Rightsfor the three year performance periodfrom 1 July 2018to 30 June 2021, with avesting date of 30 September 2021, asperformance conditions were not met.
	Forfeiture of 35,044Performance Rightsfor the one year performance period from1 July 2020to 30 June 2021,with a vestingdate of 30 June 2022, as performanceconditions were not met.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should

be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed abovetraded during a +closed period where prior written clearance wasrequired?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

+ See chapter 19 for defined terms.